Company Profile
MiNK Therapeutics, Inc. Stock Price, News & Analysis
- Ticker:
- INKT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
11.00 USD (-5.98%)
Close
Last updated: August 6, 2026
59.6M USD
Market cap
Why the stock is moving
Following the latest company update, “MiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research Symposium”, INKT closed down 5.98% at $11.00 on Aug 6, 2026. The move occurred in the trading session associated with this clinical readout update.
Company overview
Allogeneic iNKT Cell Therapy Company
MiNK Therapeutics develops allogeneic invariant natural killer T-cell therapies and precision immune-modulating medicines. Its platform is designed to connect innate and adaptive immunity across cancer, autoimmune disease, and states of severe immune dysfunction.
AgenT-797 Lead Asset
AgenT-797 is an off-the-shelf, cryopreserved iNKT-cell therapy that does not require lymphodepletion or HLA matching. These characteristics may support use in severe acute lung injury, critical illness, and other settings involving immune dysregulation.
Off-the-Shelf Treatment Model
The ability to store and administer AgenT-797 without patient-specific manufacturing is central to its intended use. This model may be particularly relevant in acute-care settings where rapid treatment and simplified logistics are important.
Multi-Indication Expansion
AgenT-797 is being studied in solid tumors, graft-versus-host disease, and critical pulmonary immune failure. MiNK also has TCR-based and neoantigen-targeted iNKT programs intended to achieve tissue-specific immune activation.
Future catalysts
A randomized Phase 2 trial of AgenT-797 in severe acute lung injury and respiratory distress has begun, with preliminary data expected in the second half of 2026.
The study uses a seamless Phase 2/3 operational framework that could support more efficient progression into late-stage development if the randomized Phase 2 results are favorable.
Recent news
- 01
- 02
- 03
MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting
Source: MiNK Therapeutics, Inc.
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of MiNK Therapeutics, Inc. (INKT)?
MiNK Therapeutics, Inc. (INKT) most recently closed at 11.00 USD, a -5.98% move versus the previous session.
What is the market cap of MiNK Therapeutics, Inc. (INKT)?
MiNK Therapeutics, Inc. currently has a market capitalization of 59.6M USD on BioPharmSignal.
What does MiNK Therapeutics, Inc. do?
Allogeneic iNKT Cell Therapy Company MiNK Therapeutics develops allogeneic invariant natural killer T-cell therapies and precision immune-modulating medicines. Its platform is designed to connect innate and adaptive immunity across cancer, autoimmune disease, and states of severe immune dysfunction. AgenT-797 Lead Asset AgenT-797 is an off-the-shelf,...
On which exchange is INKT stock listed?
MiNK Therapeutics, Inc. (INKT) is associated with NASDAQ, United States, Biopharma.
What is Allogeneic?
Allogeneic iNKT Cell Therapy Company MiNK Therapeutics develops allogeneic invariant natural killer T-cell therapies and precision immune-modulating medicines.
Which conditions is MiNK Therapeutics, Inc. targeting with Allogeneic?
MiNK Therapeutics, Inc. is associated with cancer therapeutics, respiratory disease based on its company overview and current catalyst commentary.
How does MiNK Therapeutics, Inc. describe recent progress with Allogeneic?
A randomized Phase 2 trial of AgenT-797 in severe acute lung injury and respiratory distress has begun, with preliminary data expected in the second half of 2026. The study uses a seamless Phase 2/3 operational framework that could support more efficient progression into late-stage development if the randomized Phase 2 results are favorable.
What is Cell?
Allogeneic iNKT Cell Therapy Company MiNK Therapeutics develops allogeneic invariant natural killer T-cell therapies and precision immune-modulating medicines.